Primary Ciliary Dyskinesia (PCD)

1
Pipeline Programs
1
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

ReCode Therapeutics
ReCode TherapeuticsCA - Menlo Park
1 program
1
RCT1100Phase 11 trial
Active Trials
NCT06633757Active Not Recruiting12Est. Dec 2025

Trial Timeline

Clinical trial activity over time

2024
2025
2026
ReCode TherapeuticsRCT1100

Clinical Trials (1)

Total enrollment: 12 patients across 1 trials

NCT06633757ReCode TherapeuticsRCT1100

Study of Inhaled RCT1100 in Adults With PCD Caused by Pathogenic Mutations in the DNAI1 Gene to Measure Mucociliary Clearance

Start: Oct 2024Est. completion: Dec 202512 patients
Phase 1Active Not Recruiting

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 companies competing in this space